Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.

ABSTRACT:

Background

Antiretroviral therapy initiation for HIV-1 infection is associated with 2% to 6% loss of bone mineral density (BMD).

Objective

To evaluate the effect of vitamin D3 plus calcium supplementation on bone loss associated with antiretroviral therapy initiation.

Design

48-week prospective, randomized, double-blind, placebo-controlled study. (ClinicalTrials.gov: NCT01403051).

Setting

39 AIDS Clinical Trials Group units.

Patients

Adults with antiretroviral therapy-naive HIV.

Measurements

BMD by dual-energy x-ray absorptiometry, 25-hydroxyvitamin D levels, and other laboratory assessments.

Results

165 eligible patients were randomly assigned (79 received vitamin D3 plus calcium and 86 received placebo). The study groups were well-balance

SUBMITTER: Overton ET 

PROVIDER: S-EPMC4608553 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature